Real-World Experience With Secukinumab for Hidradenitis Suppurativa: A Multicenter Retrospective Analysis of 263 Patients From the SECU-SPAIN Study.

There is no consensus on the response rates of secukinumab, as findings from phase III trials differ from those reported in clinical-practice studies. This study aimed to assess the mid-term safety and efficacy profile of secukinumab in patients with moderate-to-severe Hidradenitis suppurativa (HS).

Detalhes bibliográficos
Autores: Martorell A, Vilarrasa-Rull E, Fernandez-Crehuet P, Molina-Leyva A, Mansilla M, Garcia-Ruiz R, Garbayo-Salmons P, Ortiz-Salvador JM, Alfageme-Roldan F, Garcias-Ladaria J, Bassas-Vila J, Fuertes-de-Vega I, Carnero-Gonzalez L, Almenara-Blasco M, Torres-Navarro I, Aguayo-Ortiz R, Gil Pallares P, Fornons-Servent R, Gracia-Darder I, Mora-Fernández V, Corral O, Pericet-Fernandez L, Navarro F, Haselgruber S, Ochando-Ibernon G, Menéndez-Parron A, Masferrer E, Gamissans M, Solera-Talamante M, Moya M, Imbernon A, Melgosa J
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2026
País:España
Recursos:Institut d'Investigació i Innovació Parc Taulí (I3PT)
Repositorio:r-I3PT. Repositorio Institucional Producción Científica del Institut d'Investigació i Innovació Parc Taulí
OAI Identifier:oai:i3pt.fundanetsuite.com:p6815
Acesso em linha:https://i3pt.portalinvestigacion.com/publicaciones/6815
https://www.scopus.com/inward/record.uri?eid=2-s2.0-105026675160&doi=10.1016%2Fj.ad.2025.104562&partnerID=40&md5=c30728a8776441ceae863f297d3fb5b5
Access Level:acceso abierto
Palavra-chave:Anti Il17A, HS, Monoclonal antibody, Real-world evidence, Secukinumab
Descrição
Resumo:There is no consensus on the response rates of secukinumab, as findings from phase III trials differ from those reported in clinical-practice studies. This study aimed to assess the mid-term safety and efficacy profile of secukinumab in patients with moderate-to-severe Hidradenitis suppurativa (HS).

Registos relacionados